RedHill Biopharma (RDHL) Cash from Investing Activities (2012 - 2021)

RedHill Biopharma (RDHL) has 9 years of Cash from Investing Activities data on file, last reported at -$3.5 million in Q2 2021.

• Cash from Investing Activities for Q2 2021 came in at -$3.5 million, up 92.97% year-over-year; the trailing twelve-month figure through Jun 2021 was -$61.6 million (up 19.69% YoY), and the FY2025 annual result was -$5000.0, up 44.44% from the prior year.
• Cash from Investing Activities rose to -$3.5 million in Q2 2021 per RDHL's latest filing, from -$49.8 million in the prior quarter.
• Over five years, Cash from Investing Activities peaked at -$3.4 million in Q2 2019 and troughed at -$49.8 million in Q2 2020.
• A 4-year average of -$16.0 million and a median of -$4.9 million in 2017 frame the typical range for Cash from Investing Activities.
• The sharpest annual moves came in 2020 and 2021: Cash from Investing Activities sank 1368.88% in 2020, then surged 92.97% in 2021.
• A 4-year view of Cash from Investing Activities shows it stood at -$4.9 million in 2017, then jumped by 30.4% to -$3.4 million in 2019, then slumped by 1368.88% to -$49.8 million in 2020, then surged by 92.97% to -$3.5 million in 2021.
• Business Quant data shows RDHL's Cash from Investing Activities at -$3.5 million in Q2 2021, -$49.8 million in Q2 2020, and -$3.4 million in Q2 2019.